Holen Sie sich die Stockscreener-App
24.41
0.00%
0.00
Handel nachbörslich:
24.36
-0.05
-0.20%
Schlusskurs vom Vortag:
$24.41
Offen:
$24.88
24-Stunden-Volumen:
63,861
Relative Volume:
0.66
Marktkapitalisierung:
$815.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+6.13%
1M Leistung:
+8.68%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$23.75
$25.00
1-Wochen-Bereich:
$21.40
$25.05
52-Wochen-Spanne:
$20.15
$30.56
Spyglass Pharma Inc Stock (SGP) Company Profile
Firmenname
Spyglass Pharma Inc
Sektor
Branche
Telefon
949-284-6904
Adresse
27081 ALISO CREEK ROAD, ALISO VIEJO
Compare SGP vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SGP
Spyglass Pharma Inc
|
24.41 | 815.94M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 109.34B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 74.35B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 50.44B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 39.78B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.02B | 5.36B | 287.73M | 924.18M | 2.5229 |
Spyglass Pharma Inc Stock (SGP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2026-03-03 | Eingeleitet | Citigroup | Buy |
| 2026-03-03 | Eingeleitet | Jefferies | Buy |
| 2026-03-03 | Eingeleitet | Leerink Partners | Outperform |
| 2026-03-03 | Eingeleitet | Stifel | Buy |
Spyglass Pharma Inc Aktie (SGP) Neueste Nachrichten
Spyglass Pharma (SGP) Earnings Date and Reports 2026 $SGP - MarketBeat
What fair value gap SpyGlass Pharma (SGP)? (Buying Pressure) 2026-05-01Gap Up Stocks - Newser
SGP Ownership | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
Eye care firm SpyGlass Pharma soars 65% in trading debut - MSN
Spyglass Pharma (SGP) Stock Chart and Price History 2026 $SGP - MarketBeat
SGP Technical Analysis | Trend, Signals & Chart Patterns | SPYGLASS PHARMA INC (NASDAQ:SGP) - ChartMill
All News for SGP : SpyGlass Pharma, Inc. - Zacks Investment Research
Dividend HistorySpyGlass Pharma, Inc. (SGP) - Zacks Investment Research
Is SpyGlass Pharma (SGP) Stock Good for Long Term | Price at $22.30, Down 0.71%Popular Market Picks - Newser
SpyGlass Pharma, Inc.: Fundamental Analysis and Financial Ratings | SGP | US85220G1094 - marketscreener.com
SGP: SpyGlass Pharma, Inc.Insider Transations - Zacks Investment Research
SpyGlass Pharma, Inc. (SGP) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
SpyGlass Pharma Reports Fourth Quarter and Full-Year 2025 Results - VisionMonday.com
SpyGlass Pharma, Inc. (SGP) stock price, news, quote and history - Yahoo Finance UK
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target By Investing.com - Investing.com Canada
Stifel reiterates Buy on SpyGlass Pharma stock, $42 target - Investing.com
SpyGlass Pharma’s BIM-IOL System: Transforming Glaucoma and Ocular Hypertension Treatment with Long-Acting Drug Delivery Solutions - Minichart
SpyGlass Pharma (NASDAQ: SGP) outlines long-acting glaucoma implant pipeline - Stock Titan
[8-K] SpyGlass Pharma, Inc. Reports Material Event - Stock Titan
97% stopped glaucoma drops in SpyGlass eye implant study - Stock Titan
SpyGlass Pharma Reports Fourth Quarter and Full Year 2025 Earnings and Provides a Corporate Update - GlobeNewswire
New Glaucoma Treatment Uses Eye Implant for Three-Year Drug Delivery - University of Colorado Anschutz
SpyGlass Pharma, Inc.(NasdaqGS: SGP) added to S&P TMI Index - marketscreener.com
SGP Stock Price, News & Analysis - Stock Titan
SpyGlass Valued at $900M After IPO - Orange County Business Journal
Spyglass Pharma (SGP) Insider Trading Activity 2026 $SGP - MarketBeat
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at HC Wainwright - Defense World
H.C. Wainwright initiates SpyGlass Pharma stock coverage with buy rating By Investing.com - Investing.com Canada
SpyGlass Pharma reports positive 12-month Phase 1/2 BIM-IOL results with high drop-free rates - TradingView
SpyGlass Pharma reports positive 12-month glaucoma device trial data - Investing.com Australia
SpyGlass Pharma reports positive 12-month glaucoma device trial data By Investing.com - Investing.com India
SpyGlass Pharma Announces Positive Topline 12-Month Phase 1/2 Trial Results for Its Innovative BIM-IOL System - The Manila Times
Spyglass Pharma surges on public debut; Agomab falls - MSN
Spyglass Pharma (NASDAQ:SGP) Upgraded at Zacks Research - Defense World
Polsinelli Advises SpyGlass Pharma on Intellectual Property Matters in Initial Public Offering - The National Law Review
SpyGlass Pharma to Participate in the Jefferies Biotech on the Beach Summit - Bitget
Spyglass Pharma (NASDAQ:SGP) Coverage Initiated by Analysts at Citigroup - Defense World
Latest SGP ETF News Today | Earnings, Events & Price Alerts - Intellectia AI
Stifel Initiates Coverage of SpyGlass Pharma (SGP) with Buy Recommendation - Nasdaq
Leerink initiates SpyGlass Pharma stock with Outperform rating By Investing.com - Investing.com Canada
Spyglass Pharma (NASDAQ:SGP) Now Covered by Stifel Nicolaus - MarketBeat
Jefferies initiates SpyGlass Pharma stock with buy rating on glaucoma drug - Investing.com Canada
Leerink Initiates SpyGlass Pharma at Outperform With $42 Price Target - marketscreener.com
Jefferies Initiates SpyGlass Pharma at Buy With $62 Price Target - marketscreener.com
Stifel initiates SpyGlass Pharma stock with buy rating on glaucoma device potential - Investing.com Canada
This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tue - Benzinga
SGP SEC FilingsSpyGlass Pharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
SpyGlass Pharma (SGP) Stock Analysis Report | Financials & Insights - Benzinga Japan
Spyglass Pharma (SGP) Stock Price, News & Analysis $SGP - MarketBeat
Top Spyglass Pharma (SGP) Competitors 2026 - MarketBeat
SGP News Today | Why did Spyglass Pharma stock go down today? $SGP - MarketBeat
Finanzdaten der Spyglass Pharma Inc-Aktie (SGP)
Es liegen keine Finanzdaten für Spyglass Pharma Inc (SGP) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.14%
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):